CareDx, Inc (CDNA) |
| 28.76 0.25 (0.88%) 07-13 16:00 |
| Open: | 27.875 |
| High: | 28.81 |
| Low: | 27.875 |
| Volume: | 538,076 |
| Market Cap: | 1,486(M) |
| PE Ratio: | 34.24 |
| Exchange: | NASDAQ Global Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 35.04 |
| Resistance 1: | 30.00 |
| Pivot price: | 28.10 |
| Support 1: | 24.82 |
| Support 2: | 21.62 |
| 52w High: | 30 |
| 52w Low: | 10.96 |
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
| EPS | -0.160 |
| Book Value | 6.110 |
| PEG Ratio | 0.00 |
| Gross Profit | 5.505 |
| Profit Margin (%) | -1.98 |
| Operating Margin (%) | 1.53 |
| Return on Assets (ttm) | -1.8 |
| Return on Equity (ttm) | -2.4 |
Mon, 13 Jul 2026
How Caredx Inc. (CDNA) Affects Rotational Strategy Timing - Stock Traders Daily
Tue, 07 Jul 2026
CareDx (CDNA) director receives 1,746-share quarterly stock grant as compensation - Stock Titan
Tue, 07 Jul 2026
CareDx (CDNA) exits lab products and acquires Naveris to expand $12B market - Stock Titan
Tue, 07 Jul 2026
CareDx Completes Naveris Acquisition and Expands Oncology Reach - Yahoo Finance
Tue, 07 Jul 2026
CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder (CDNA) - Seeking Alpha
Sun, 05 Jul 2026
Enterprise value to EBITDA forward of CareDx, Inc. – NASDAQ:CDNA - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |